此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial (ADAPT)

2026年7月7日 更新者:Nisha Acharya

The goal of this clinical trial is to learn whether children and young adults with well-controlled juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior uveitis can safely take adalimumab (or biosimilar) injections less often while maintaining control of their disease.

The main question it aims to answer is: can adalimumab/biosimilar injections be given less frequently without uveitis (eye inflammation) or arthritis (joint inflammation) returning?

Researchers will compare adalimumab/biosimilar injection schedules of every 2 weeks, 4 weeks, 8 weeks, and 12 weeks to determine how injection frequency affects disease control.

Participants will:

  • Take adalimumab/biosimilar injections every 2, 4, 8, or 12 weeks.
  • Attend study visits every 6 weeks over 24 weeks, with an additional follow-up visit at 48 weeks for checkups, tests, and questionnaires.
  • Keep a diary of how often they take adalimumab/biosimilar and other drugs they take for their uveitis/arthritis.

研究概览

研究类型

介入性

注册 (估计的)

160

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Florence、意大利、50139
        • Meyer Children's Hospital
        • 首席研究员:
          • Gabriele Simonini
        • 接触:
        • 首席研究员:
          • Ilaria Maccora
    • California
      • Los Angeles、California、美国、90095
        • University of California, Los Angeles
        • 首席研究员:
          • Edmund Tsui, MD
        • 接触:
      • Sacramento、California、美国、95817
        • University of California, Davis
        • 接触:
        • 首席研究员:
          • Parisa Emami-Naeini, MD MPH
        • 首席研究员:
          • Angel Herrera-Guerra, MD PhD
      • San Francisco、California、美国、94143
        • University of California, San Francisco
        • 首席研究员:
          • Nisha Acharya, MD
        • 接触:
        • 副研究员:
          • John Gonzales, MD
        • 副研究员:
          • Thuy Doan, MD PhD
    • Florida
      • Miami、Florida、美国、33136
        • University of Miami
        • 接触:
        • 首席研究员:
          • Stephanie Llop, MD
        • 副研究员:
          • Janet Davis, MD
    • Missouri
      • Kansas City、Missouri、美国、64108
        • Children's Mercy Hospital
        • 接触:
        • 首席研究员:
          • Ashley Cooper, MD
        • 首席研究员:
          • Erin Stahl, MD
    • Ohio
      • Cincinnati、Ohio、美国、45229
        • Cincinnati Children's Hospital
        • 首席研究员:
          • Virginia Miraldi Utz, MD
        • 首席研究员:
          • Sheila Angeles-Han, MD
        • 接触:
    • Tennessee
      • Nashville、Tennessee、美国、37212
        • Vanderbilt University Medical Center
        • 接触:
        • 首席研究员:
          • Sapna Gangaputra, MD MPH
        • 首席研究员:
          • Thomas (Brent) Graham, MD MS
    • Texas
      • Austin、Texas、美国、78712
        • University of Texas, Austin
        • 接触:
        • 首席研究员:
          • Eric Crowell, MD MPH
    • Utah
      • Salt Lake City、Utah、美国、84132
        • University of Utah Health
        • 接触:
        • 首席研究员:
          • Marissa Larochelle, MD
      • Bristol、英国、BS1 3NU
        • University Hospitals Bristol and Weston
        • 首席研究员:
          • A V Ramanan
        • 接触:
        • 首席研究员:
          • Catherine Guly
      • Leicester、英国、LE1 5WW
        • University Hospitals of Leicester
        • 接触:
        • 首席研究员:
          • Arani Sridhar
        • 首席研究员:
          • Bharat Kapoor
      • Liverpool、英国、L14 5AB
        • Alder Hey Children's Hospital
        • 首席研究员:
          • Gavin Cleary
        • 首席研究员:
          • Jose Gonzalez-Martin
        • 接触:
      • London、英国、WC1N 3JH
        • Great Ormond Street Hospital
        • 首席研究员:
          • Elena Moraitis
        • 首席研究员:
          • Harry Petrushkin
        • 接触:
        • 副研究员:
          • Lola Solebo
      • Manchester、英国、M13 9WL
        • Manchester University NHS Foundation Trust
        • 接触:
        • 首席研究员:
          • Jane Ashworth
      • Newcastle upon Tyne、英国、NE1 4LP
        • Great North Children's Hospital
        • 首席研究员:
          • Sharmila Jandial
        • 接触:
      • Norwich、英国、NR4 6TZ
        • Norfolk and Norwich University Hospital
        • 首席研究员:
          • Kate Armon
        • 首席研究员:
          • Narman Puvanachandra
        • 接触:
      • Sheffield、英国、S10 2TQ
        • Sheffield Children's Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Stated willingness to comply with all study procedures and availability for the duration of the study period
  • History of juvenile idiopathic arthritis (JIA) or chronic anterior uveitis (CAU), diagnosed prior to 16 years of age (patient may be older than 16 at time of enrollment)
  • ≥2 years of age (per FDA approval for use in children with polyarticular JIA)
  • Weight must be ≥15kg
  • Formal diagnosis of JIA-associated uveitis or CAU with no other suspected etiology
  • ≥24 consecutive months of controlled ocular inflammation (≤0.5+ anterior chamber cell, ≤0.5+ vitreous haze, and no active retinal/choroidal lesions in either eye)
  • ≥24 consecutive months of controlled arthritis verified by a pediatric rheumatologist if defined as JIA-associated uveitis
  • ≥24 consecutive months of treatment with adalimumab or biosimilar of adalimumab
  • ≥180 days on a stable dose of adalimumab or biosimilar of adalimumab; dose must be no greater than 20mg (if weight <30kg), or 40mg (if weight ≥30kg), injected every two weeks
  • If on biosimilar of adalimumab, ≥90 days on the biosimilar
  • Ability to continue to obtain commercial supply of adalimumab or biosimilar
  • If on a conventional disease-modifying anti-rheumatic drug (cDMARD) (injectable or oral methotrexate, mycophenolate mofetil, azathioprine, or leflunomide), dose must be ≤25 mg weekly for methotrexate, ≤3 g daily for mycophenolate mofetil, ≤250 mg daily for azathioprine, or ≤20 mg daily for leflunomide; dose and route of administration must be stable for ≥90 days
  • Willingness to limit consumption of alcohol during the study period
  • Agreement to avoid live attenuated vaccinations
  • Agreement to use highly effective contraception or abstinence for ≥28 days prior to screening and throughout the study period (for males and females of reproductive age)
  • Suitable, in the opinion of the Investigator, to continue treatment with adalimumab/biosimilar per regional labeling

Exclusion Criteria:

  • History of acute anterior uveitis characterized by redness and symptoms, including but not limited to floaters, pain, and light sensitivity
  • Intraocular surgery in the past 90 days or planned surgery in the next 24 weeks
  • Severe cataract or opacity preventing view to the posterior pole in both eyes
  • Chronic hypotony (<5mmHg for ≥90 days) in either eye
  • Treatment with oral corticosteroids or intraocular corticosteroid injection within the last 24 weeks
  • Use of topical corticosteroid eye drops within the last 90 days
  • Use of nonsteroidal anti-inflammatory drug (NSAID) eye drops within the last 90 days
  • Pregnancy or lactation (a pregnancy test will be conducted at baseline and follow-up visits for females post-menarche)
  • Presence of intraretinal or subretinal fluid in either eye
  • Prior safety or tolerability issues with adalimumab
  • History of cancer, active tuberculosis, or hepatitis B
  • Other medical condition expected to dictate treatment course during the study
  • Any of the following laboratory test results on their most recent tests within the past 90 days prior to screening/enrollment: leukocyte count <2500, platelet count ≤75000, hemoglobin<9.0, aspartate transaminase (AST) or alanine transaminase (ALT) ≥ 2 times the upper limit of normal range, creatinine ≥1.5

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
有源比较器:2-Week Dose
Participants receive adalimumab/biosimilar at their current weight-based dose every 2 weeks for 24 weeks, continuing in accordance with current standard of care practice.
Adalimumab is a fully human monoclonal anti-tumor necrosis factor alpha antibody - a biologic, immunomodulatory drug. Adalimumab (20mg or 40mg) is a clear, colorless solution available as an injectable auto-pen or pre-filled syringe for subcutaneous injection. All FDA-approved adalimumab biosimilars are allowed for this trial and include: Abrilada (adalimumab-afzb), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm), Hadlima (adalimumab-bwwd), Hulio (adalimumab-fkjp), Hyrimoz (adalimumab-adaz), Idacio (adalimumab-aacf), Simlandi (adalimumab-ryvk), Yuflyma (adalimumab-aaty), and Yusimry (adalimumab-aqvh).
其他名称:
  • 修美乐
  • 海里莫兹
  • 伊达西奥
  • 胡里奥
  • Simlandi
  • Abrilada
  • Amjevita
  • Cyltezo
  • Hadlima
  • Yuflyma
  • Yusimry
实验性的:4-Week Dose
Participants receive adalimumab/biosimilar at their current weight-based dose every 4 weeks for 24 weeks.
Adalimumab is a fully human monoclonal anti-tumor necrosis factor alpha antibody - a biologic, immunomodulatory drug. Adalimumab (20mg or 40mg) is a clear, colorless solution available as an injectable auto-pen or pre-filled syringe for subcutaneous injection. All FDA-approved adalimumab biosimilars are allowed for this trial and include: Abrilada (adalimumab-afzb), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm), Hadlima (adalimumab-bwwd), Hulio (adalimumab-fkjp), Hyrimoz (adalimumab-adaz), Idacio (adalimumab-aacf), Simlandi (adalimumab-ryvk), Yuflyma (adalimumab-aaty), and Yusimry (adalimumab-aqvh).
其他名称:
  • 修美乐
  • 海里莫兹
  • 伊达西奥
  • 胡里奥
  • Simlandi
  • Abrilada
  • Amjevita
  • Cyltezo
  • Hadlima
  • Yuflyma
  • Yusimry
实验性的:8-Week Dose
Participants receive adalimumab/biosimilar at their current weight-based dose every 8 weeks for 24 weeks.
Adalimumab is a fully human monoclonal anti-tumor necrosis factor alpha antibody - a biologic, immunomodulatory drug. Adalimumab (20mg or 40mg) is a clear, colorless solution available as an injectable auto-pen or pre-filled syringe for subcutaneous injection. All FDA-approved adalimumab biosimilars are allowed for this trial and include: Abrilada (adalimumab-afzb), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm), Hadlima (adalimumab-bwwd), Hulio (adalimumab-fkjp), Hyrimoz (adalimumab-adaz), Idacio (adalimumab-aacf), Simlandi (adalimumab-ryvk), Yuflyma (adalimumab-aaty), and Yusimry (adalimumab-aqvh).
其他名称:
  • 修美乐
  • 海里莫兹
  • 伊达西奥
  • 胡里奥
  • Simlandi
  • Abrilada
  • Amjevita
  • Cyltezo
  • Hadlima
  • Yuflyma
  • Yusimry
实验性的:12-Week Dose
Participants receive adalimumab/biosimilar at their current weight-based dose every 12 weeks for 24 weeks.
Adalimumab is a fully human monoclonal anti-tumor necrosis factor alpha antibody - a biologic, immunomodulatory drug. Adalimumab (20mg or 40mg) is a clear, colorless solution available as an injectable auto-pen or pre-filled syringe for subcutaneous injection. All FDA-approved adalimumab biosimilars are allowed for this trial and include: Abrilada (adalimumab-afzb), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm), Hadlima (adalimumab-bwwd), Hulio (adalimumab-fkjp), Hyrimoz (adalimumab-adaz), Idacio (adalimumab-aacf), Simlandi (adalimumab-ryvk), Yuflyma (adalimumab-aaty), and Yusimry (adalimumab-aqvh).
其他名称:
  • 修美乐
  • 海里莫兹
  • 伊达西奥
  • 胡里奥
  • Simlandi
  • Abrilada
  • Amjevita
  • Cyltezo
  • Hadlima
  • Yuflyma
  • Yusimry

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Cumulative Incidence of Treatment Failure
大体时间:From baseline to 24 weeks post-randomization

Proportion of participants in each treatment arm experiencing treatment failure by Week 24.

Treatment failure is defined by recurrence of ocular inflammation (at least one of the following in at least one eye):

  • >0.5+ anterior chamber (AC) cell at a single visit as defined by the Standardization of Uveitis Nomenclature (SUN) criteria
  • >0.5+ vitreous haze at a single visit
  • Active retinal/choroidal inflammation and/or macular edema in either eye at a single visit. Macular edema is defined as central subfield thickness on optical coherence tomography (OCT) >2 standard deviations above normal thickness (>320µm on Spectralis or >300µm on Zeiss or Topcon) and having a greater than 20% increase from baseline and/or presence of intraretinal or subretinal fluid.

Treatment failure may also be defined as recurrence of joint disease persistent and severe enough to necessitate unmasking to manage the arthritis recurrence.

From baseline to 24 weeks post-randomization

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月1日

初级完成 (估计的)

2030年5月1日

研究完成 (估计的)

2030年11月1日

研究注册日期

首次提交

2026年7月7日

首先提交符合 QC 标准的

2026年7月7日

首次发布 (实际的)

2026年7月13日

研究记录更新

最后更新发布 (实际的)

2026年7月13日

上次提交的符合 QC 标准的更新

2026年7月7日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅